|1.||Kondo, Takao: 1 article (11/2002)|
|2.||Komorita, Naruyasu: 1 article (11/2002)|
|3.||Nakamura, Norifumi: 1 article (11/2002)|
|4.||Yoshikawa, Tsutomu: 1 article (11/2002)|
|5.||Miyazaki, Mizuo: 1 article (11/2002)|
|6.||Kobayashi, Fujio: 1 article (11/2002)|
|7.||Imada, Teruaki: 1 article (11/2002)|
|8.||Naito, Koji: 1 article (11/2002)|
11/01/2002 - "Taken together, these findings suggest that the specific chymase inhibitor Y-40613 may ameliorate symptoms of AD through the dual inhibition of the chymase-dependent IgE production pathway and itching sensation."
11/01/2002 - "We found that Y-40613 (2-[5-amino-2-(4-fluorophenyl)-1,6-dihydro-6-oxo-1-pyrimidinyl]-N-[1-[(5-methoxycarbonyl-2-benzoxazolyl)carbonyl]-2-phenylethyl]acetamide) dose-dependently suppressed the scratching response in a mouse pruritus model, with inhibitory efficacy enhanced by combination with conventional drugs, suggesting that chymase contributes to the development of pruritus by a unique mechanism or mechanisms. "
|2.||Contact Dermatitis (Eczema, Contact)
|2.||Immunoglobulin E (IgE)